Review
TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors
Christine E. Jo BSc,
Melinda Gooderham MD, MSc, FRCPC,
Jennifer Beecker MD, CCFP(EM), FRCPC, FAAD,
Christine E. Jo BSc
Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
Search for more papers by this authorMelinda Gooderham MD, MSc, FRCPC
Department of Medicine, Queen's University, Kingston, Ontario, Canada
SKiN Centre for Dermatology, Peterborough, Ontario, Canada
Probity Medical Research Inc., Waterloo, Ontario, Canada
Search for more papers by this authorCorresponding Author
Jennifer Beecker MD, CCFP(EM), FRCPC, FAAD
Probity Medical Research Inc., Waterloo, Ontario, Canada
Division of Dermatology, University of Ottawa, Ottawa, Ontario, Canada
Correspondence
Jennifer Beecker md, ccfp(em), frcpc, faad
Division of Dermatology
The Ottawa Hospital
1053 Carling Ave, Parkdale Clinic, Fourth floor
Ottawa
ON
Canada
E-mail: [email protected]
Search for more papers by this authorChristine E. Jo BSc,
Melinda Gooderham MD, MSc, FRCPC,
Jennifer Beecker MD, CCFP(EM), FRCPC, FAAD,
Christine E. Jo BSc
Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
Search for more papers by this authorMelinda Gooderham MD, MSc, FRCPC
Department of Medicine, Queen's University, Kingston, Ontario, Canada
SKiN Centre for Dermatology, Peterborough, Ontario, Canada
Probity Medical Research Inc., Waterloo, Ontario, Canada
Search for more papers by this authorCorresponding Author
Jennifer Beecker MD, CCFP(EM), FRCPC, FAAD
Probity Medical Research Inc., Waterloo, Ontario, Canada
Division of Dermatology, University of Ottawa, Ottawa, Ontario, Canada
Correspondence
Jennifer Beecker md, ccfp(em), frcpc, faad
Division of Dermatology
The Ottawa Hospital
1053 Carling Ave, Parkdale Clinic, Fourth floor
Ottawa
ON
Canada
E-mail: [email protected]
Search for more papers by this authorConflicts of interest: Dr. Melinda Gooderham has been an investigator, speaker, advisor, or consultant for AbbVie, Amgen, Akros, Arcutis, BMS, Boehringer Ingelheim, Celgene, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Janssen, Kyowa Kirin, LEO Pharma, Medimmune, Merck, Novartis, Pfizer, Regeneron, Sanofi, Genzyme, Sun Pharma, UCB, and Valeant/Bausch Health. Dr. Jennifer Beecker has been an investigator, speaker, advisor, or consultant for Abbvie, Amgen, Celgene, CeraVe, Lilly, Galderma, Janssen, Johnson and Johnson, La Roche Posay, Leo, Novartis, Pfizer, Sanofi Genzyme, and Vichy. Ms. Jo has no conflicts of interest to declare.
Funding source: None.
Abstract
Increasing understanding of cytokines as major drivers of immune-mediated diseases has revolutionized targeted treatments for these conditions. As the pathogenesis of autoimmune conditions is mediated by a complex interplay of various cytokines, Janus kinase (JAK) inhibitors have been of particular interest due to their ability to target multiple cytokines simultaneously. However, due to safety concerns with first generation JAK inhibitors, most notably from JAK2 and JAK3 inhibition, interest has shifted to more selective inhibition of TYK2. Three key TYK2 inhibitors that have advanced furthest in clinical trials for treatment of dermatologic autoimmune conditions are deucravacitinib (BMS-986165), brepocitinib (PF-06700841), and PF-06826647. This review outlines the current understanding of the efficacy and safety of these three TYK2 inhibitors from completed phase I and II studies and summarizes studies currently in progress for dermatologic conditions.
References
- 1O'Shea JJ, Gadina M. Selective Janus kinase inhibitors come of age. Nat Rev Rheumatol 2019; 15: 74. https://doi.org/10.1038/s41584-018-0155-9
- 2Babon JJ, Lucet IS, Murphy JM, Nicola NA, Varghese LN. The molecular regulation of Janus kinase (JAK) activation. Biochem J 2014; 462: 1–13. https://doi.org/10.1042/BJ20140712
- 3T. Virtanen A, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: prospects in Inflammatory and Autoimmune Diseases. BioDrugs 2019; 33: 15–32. https://doi.org/10.1007/s40259-019-00333-w
- 4Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discovery 2017; 16: 843–862.
- 5Gündüz Ö. JAK/STAT pathway modulation: does it work in dermatology? Dermatol Ther 2019; 32: https://doi.org/10.1111/dth.12903
- 6Ciechanowicz P, Rakowska A, Sikora M, Rudnicka L. JAK-inhibitors in dermatology: current evidence and future applications. J Dermatol Treatment. 2019; 30: 648–658. https://doi.org/10.1080/09546634.2018.1546043
- 7Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal 2017; 15: 23. https://doi.org/10.1186/s12964-017-0177-y
- 8Crowley EL, Fine SC, Katipunan KK, Gooderham MJ. The use of Janus kinase inhibitors in alopecia areata: a review of the literature. J Cutan Med Surg 2019; 23: 289–297. https://doi.org/10.1177/1203475418824079
- 9van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367: 508–519. https://doi.org/10.1056/NEJMoa1112072
- 10Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis. JAMA Oncol. 2018; 4: 652–https://doi.org/10.1001/jamaoncol.2017.5818
- 11Mascarenhas J, Hoffman R, Talpaz M, et al. Results of the persist-2 Phase 3 study of pacritinib (PAC) versus best available therapy (BAT), including ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl. Blood 2016; 128: LBA-5. https://doi.org/10.1182/blood.V128.22.LBA-5.LBA-5
- 12Macchi P, Villa A, Giliani S, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995; 377: 65–68. https://doi.org/10.1038/377065a0
- 13Genovese MC, van Vollenhoven RF, Pacheco-Tena C, Zhang Y, Kinnman N. VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis. Arthritis & Rheumatology (Hoboken, NJ). 2016; 68: 46–55. https://doi.org/10.1002/art.39473
- 14Velazquez L, Fellous M, Stark GR, Pellegrini S. A protein tyrosine kinase in the interferon αβ signaling pathway. Cell 1992; 70: 313–322. https://doi.org/10.1016/0092-8674(92)90105-L
- 15Rodig SJ, Meraz MA, White JMichael, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the JAKS in cytokine-induced biologic responses. Cell 1998; 93: 373–383. https://doi.org/10.1016/s0092-8674(00)81166-6
- 16Neubauer H, Cumano A, Müller M, Wu H, Huffstadt U, Pfeffer K. JAK2 deficiency defines an essential developmental checkpoint in definitivehematopoiesis. Cell 1998; 93: 397–409. https://doi.org/10.1016/S0092-8674(00)81168-X
- 17Parganas E, Wang D, Stravopodis D, et al. JAK2 is essential for signaling through a variety of cytokine receptors. Cell 1998; 93: 385–395. https://doi.org/10.1016/s0092-8674(00)81167-8
- 18Karaghiosoff M, Neubauer H, Lassnig C, et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 2000; 13: 549–560.
- 19Shimoda K, Kato K, Aoki K, et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 2000; 13: 561–571.
- 20Shaw MH, Boyartchuk V, Wong S, et al. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc Natl Acad Sci USA 2003; 100: 11594–11599. https://doi.org/10.1073/pnas.1930781100
- 21Minegishi Y, Saito M, Morio T, et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 2006; 25: 745–755. https://doi.org/10.1016/j.immuni.2006.09.009
- 22Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci 2019; 20: https://doi.org/10.3390/ijms20061475
- 23Conrad C, Gilliet M. Psoriasis: from pathogenesis to targeted therapies. Clinic Rev Allerg Immunol 2018; 54: 102–113. https://doi.org/10.1007/s12016-018-8668-1
- 24Blauvelt A. Dual inhibition of IL-12/IL-23 and selective inhibition of IL-23 in psoriasis. In: PS Yamauchi, ed. Biologic and Systemic Agents in Dermatology. Springer International Publishing, 2018: 123–131. https://doi.org/10.1007/978-3-319-66884-0_14
10.1007/978-3-319-66884-0_14 Google Scholar
- 25Lebwohl M, Langley RG, Zhu Y, et al. Use of dose–exposure–response relationships in Phase 2 and phase 3 guselkumab studies to optimize dose selection in psoriasis. J European Academy Dermatol Venereol 2019; 33: 2082–2086. https://doi.org/10.1111/jdv.15668
- 26Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. The Lancet 2017; 390: 276–288. https://doi.org/10.1016/S0140-6736(17)31279-5
- 27Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. The Lancet 2018; 392: 650–661. https://doi.org/10.1016/S0140-6736(18)31713-6
- 28Sohn SJ, Barrett K, Van Abbema A, et al. A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. J Immunol 2013; 191: 2205–2216. https://doi.org/10.4049/jimmunol.1202859
- 29Benhadou F, Mintoff D, del Marmol V. Psoriasis: keratinocytes or immune cells – which is the trigger? DRM 2019; 235: 91–100. https://doi.org/10.1159/000495291
- 30Strange A, Capon F, Spencer CC, et al. Genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010; 42: 985–990. https://doi.org/10.1038/ng.694
- 31Malik K, Guttman-Yassky E. Cytokine targeted therapeutics for alopecia areata: lessons from atopic dermatitis and other inflammatory skin diseases. J Investigative Dermatology Symposium Proceedings 2018; 19: S62–S64. https://doi.org/10.1016/j.jisp.2017.10.005
- 32Trüeb RM, Dias MFRG. Alopecia areata: a comprehensive review of pathogenesis and management. Clinic Rev Allerg Immunol 2018; 54: 68–87. https://doi.org/10.1007/s12016-017-8620-9
- 33Paus R, Bertolini M. The role of hair follicle immune privilege collapse in alopecia areata: status and perspectives. J Investig Dermatol Symp Proc 2013; 16: S25–27. https://doi.org/10.1038/jidsymp.2013.7
- 34Rajabi F, Drake LA, Senna MM, Rezaei N. Alopecia areata: a review of disease pathogenesis. Br J Dermatol 2018; 179: 1033–1048. https://doi.org/10.1111/bjd.16808
- 35Wang F-P, Tang X-J, Wei C-Q, Xu L-R, Mao H, Luo F-M. Dupilumab treatment in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci 2018; 90: 190–198. https://doi.org/10.1016/j.jdermsci.2018.01.016
- 36Anzai A, Wang EHC, Lee EY, Aoki V, Christiano AM. Pathomechanisms of immune-mediated alopecia. Int Immunol 2019; 31: 439–447. https://doi.org/10.1093/intimm/dxz039
- 37He X, Chen X, Zhang H, Xie T, Ye X-Y. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015–2018). Expert Opin Ther Pat 2019; 29: 137–149. https://doi.org/10.1080/13543776.2019.1567713
- 38Moslin RM, Weinstein DS, Wrobleski ST, et al. Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses. Published online November 29, 2016. Accessed July 29, 2019. https://patents.google.com/patent/US9505748B2/en
- 39Papp K, Gordon K, Thaçi D, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med 2018; 379: 1313–1321. https://doi.org/10.1056/NEJMoa1806382
- 40 An Investigational study to evaluate experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis - full text view - ClinicalTrials.gov. Accessed June 17, 2019. https://clinicaltrials.gov/ct2/show/NCT03624127
- 41 An investigational study to evaluate experimental medication bms-986165 compared to placebo and a currently available treatment in participants with moderate-to-severe plaque psoriasis - full text view - ClinicalTrials.gov. Accessed July 29, 2019. https://clinicaltrials.gov/ct2/show/NCT03611751
- 42 Bristol-Myers Squibb. A multi-center, randomized, double-blind, placebo-controlled phase 3 study to evaluate the efficacy and safety of BMS-986165 in subjects with moderate-to-severe plaque psoriasis. clinicaltrials.gov; 2020. Accessed May 17, 2020. https://clinicaltrials.gov/ct2/show/NCT04167462
- 43 An investigational study to evaluate experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis - full text view - ClinicalTrials.gov. Accessed July 29, 2019. https://clinicaltrials.gov/ct2/show/NCT03624127
- 44 An investigational study to evaluate BMS-986165 in patients with systemic lupus erythematosus - full text view - ClinicalTrials.gov. Accessed July 29, 2019. https://clinicaltrials.gov/ct2/show/NCT03252587
- 45 Dose ranging study to assess efficacy, safety and tolerability of PF-06700841 topical cream in psoriasis - full text view - ClinicalTrials.gov. Accessed June 17, 2019. https://clinicaltrials.gov/ct2/show/NCT03850483
- 46 A phase 2b Study to evaluate the efficacy and safety profile of PF-06651600 and PF-06700841 in active non-segmental vitiligo subjects - full text view - ClinicalTrials.gov. Accessed July 29, 2019. https://clinicaltrials.gov/ct2/show/NCT03715829
- 47 A dose-ranging study to evaluate efficacy and safety of PF-06700841 in systemic lupus erythematosus (SLE) - full text view - ClinicalTrials.gov. Accessed July 29, 2019. https://clinicaltrials.gov/ct2/show/NCT03845517
- 48 Dose ranging study to assess efficacy, safety, tolerability and pharmacokinetics of PF-06700841 topical cream in participants with mild or moderate atopic dermatitis - full text view - ClinicalTrials.gov. Accessed July 29, 2019. https://clinicaltrials.gov/ct2/show/NCT03903822
- 49 Pfizer. A phase 2a, multicenter, randomized, double-blind, placebo-controlled, 16-week study evaluating the safety and efficacy of Pf-06650833, Pf-06700841, and Pf-06826647 in adults with moderate to severe hidradenitis suppurativa. Published May 5, 2020. Accessed May 17, 2020. https://clinicaltrials.gov/ct2/show/NCT04092452
- 50Brown MF, Dermenci A, Fensome A, et al. Pyrazolo[1,5-a]pyrazin-4-yl derivatives. Published online August 24, 2017. Accessed July 29, 2019. https://patents.google.com/patent/US20170240552A1/en?oq=+US20170240552
- 51 A study to evaluate safety and efficacy of PF-06826647 for moderate to severe plaque psoriasis - full text view - ClinicalTrials.gov. Accessed June 17, 2019. https://clinicaltrials.gov/ct2/show/NCT03895372
- 52 Study to evaluate effectiveness and safety in subjects with moderate to severe psoriasis - full text view - ClinicalTrials.gov. Accessed July 29, 2019. https://clinicaltrials.gov/ct2/show/NCT02931838
- 53 Study to evaluate the efficacy and safety profile of PF-06651600 and PF-06700841 in subjects with alopecia areata - full text view - ClinicalTrials.gov. Accessed July 29, 2019. https://clinicaltrials.gov/ct2/show/NCT02974868
- 54Bernardis E, Castelo-Soccio L. Quantifying alopecia areata via texture analysis to automate the SALT score computation. J Investigative Dermatol Symposium Proceedings 2018; 19: S34–S40. https://doi.org/10.1016/j.jisp.2017.10.010
- 55Pfizer presents positive phase 2 data in alopecia areata during late-breaker session at the 27th European Academy of Dermatology and Venereology EADV Congress. Health & Medicine Week. 2018: 153.
- 56 PF-06651600 for the treatment of alopecia areata - full text view - ClinicalTrials.gov. Accessed July 29, 2019. https://clinicaltrials.gov/ct2/show/NCT03732807
- 57 Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis - Full Text View - ClinicalTrials.gov. Accessed July 29, 2019. https://clinicaltrials.gov/ct2/show/NCT02969018
- 58 A Safety, Tolerability, pharmacokinetics and pharmacodynamics study of pf-06700841, with bioavailability/food effect investigation - full text view - ClinicalTrials.gov. Accessed July 29, 2019. https://clinicaltrials.gov/ct2/show/NCT02310750
- 59Banfield C, Scaramozza M, Zhang W, et al. The safety, tolerability, pharmacokinetics, and pharmacodynamics of a TYK2/JAK1 inhibitor (PF-06700841) in healthy subjects and patients with plaque psoriasis. J Clinical Pharmacol 2018; 58: 434–447. https://doi.org/10.1002/jcph.1046
- 60Lin TE, HuangFu W-C, Chao M-W, et al. A novel selective JAK2 inhibitor identified using pharmacological interactions. Front Pharmacol 2018; 9: https://doi.org/10.3389/fphar.2018.01379
- 61Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 2017; 389: 266–275. https://doi.org/10.1016/S0140-6736(16)32537-5
- 62Singh JA. Filgotinib, a JAK1 Inhibitor, for treatment-resistant rheumatoid arthritis. JAMA 2019; 322: 309–311. https://doi.org/10.1001/jama.2019.9056
- 63Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018; 391: 2503–2512. https://doi.org/10.1016/S0140-6736(18)31115-2
- 64Schmieder GJ, Draelos ZD, Pariser DM, et al. Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study. Br J Dermatol 2018; 179: 54–62. https://doi.org/10.1111/bjd.16004
- 65O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 2013; 368: 161–170. https://doi.org/10.1056/NEJMra1202117
- 66Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford) 2019; 58: 953–962. https://doi.org/10.1093/rheumatology/key339
- 67Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Safety and efficacy of upadacitinib monotherapy in adolescents and adults with moderate-to-severe atopic dermatitis: results from 2 pivotal, phase 3, randomized, double-blinded, placebo-controlled studies. Oral Presentation; 2020.
- 68Bissonnette R, Luchi M, Fidelus-Gort R, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. J Dermatol Treatment 2016; 27: 332–338. https://doi.org/10.3109/09546634.2015.1115819
- 69Kahl L, Patel J, Layton M, et al. Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus. Lupus 2016; 25: 1420–1430. https://doi.org/10.1177/0961203316640910
- 70Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet 2020; 396: 255–266. https://doi.org/10.1016/S0140-6736(20)30732-7
Citing Literature
